ESR1 and neoplasm: The panel recommended that a patient should be considered to be at high risk of recurrence based on the following criteria: node-positive 1-3, ER/PR <50%, grade 2/3, tumor size of >2 cm, and Ki-67 >20% (statement no. 4) (level of evidence: 2b, 5, 5).